Metabolic sydrome and its contribution to coronary artery disease in non-diabetic subjects

Journal of the Formosan Medical Association

Volumn 103, Issue 4, 2004, Pages 317-320

  Lin, Rong Tsung ^a   Lee, Wen Jane ^a   Jeng, Chii Yeng ^a   Sheu, Wayne Huey Herng ^a   Chen, Ying Tsung ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Case control studies; Coronary artery disease; Metabolic syndrome X; Prevalence; Risk factors

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PREDICTION; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; TAIWAN; CASE CONTROL STUDY; CORONARY ARTERY ATHEROSCLEROSIS; MIDDLE AGED;

CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RISK FACTORS; TAIWAN;

EID: 3342880168     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda, Md. National Institutes of Health; 2001. NIH Publication 01-3670.
2. Ford ES, Giles WH, Dietz Wh. Prevalence of the metabolic syndrome among US adults. Findings from the third national health and nutrition examination survey. JAMA 2002;287; 356-9.
3. Weiberger MH. Diuretics and their side effects: dilemma in the treatment of hypertension. Hypertention 1988;11 (suppl II): 16-20.
4. Sheu WHH, Lee WJ, Jeng CY, et al. Coronary artery risk factor predicted by insulin resistence, plasma lipids and hypertension in nondiabetic individuals. Am J Med Sci 2000;319:84-8.
5. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein in plasma without the use of preparative ultracentrifuge. Clin Chem 1972;18:449-502.
6. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
7. Inoue S, Zimmet P. The Asia-Pacific perspective: redefining obesity and its treatment. 2000.
8. Hanson RL, Imperatore G, Bennett PH, et al: Components of the 'metabolic syndrome' and incidence of type 2 diabetes. Diabetes 2002;51:3120-7.
9. Suzuki M, Shinozaki K, Kanazawa A, et al: Insulin resistance as an independent risk factor for carotid wall thickening. Hypertension 1996;28:593-8.
10. Isomaa B, Almgren P, Tuomi, etal: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;28:583-9.
11. Reaven G: Metabolic syndrome: Pathophysiology and implications for management of cardiovascular disease. Circulation 2002;106:286-8.
12. Firrannini E, Natali A, Bell P, et al: Insulin resistance and hypersecretion in obesity. J Clin Invest 1997;100:1166-73.
13. Rose G, Blackburn H: Cardiovascular Survey Methods. Geneva: World Health Organization, 1968)monogr. no. 56).
14. Chuang SY, Chen CH, Tsai ST, et al: Clinical Identification of the metabolic syndrome in Kinmen. Acta Cardiol Sin 2002;18: 16-23.